BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Modell B, Khan M, Darlison M. Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet. 2000;355:2051-2052. [PMID: 10885361 DOI: 10.1016/s0140-6736(00)02357-6] [Cited by in Crossref: 384] [Cited by in F6Publishing: 97] [Article Influence: 18.3] [Reference Citation Analysis]
Number Citing Articles
1 Gujja P, Rosing DR, Tripodi DJ, Shizukuda Y. Iron overload cardiomyopathy: better understanding of an increasing disorder. J Am Coll Cardiol 2010;56:1001-12. [PMID: 20846597 DOI: 10.1016/j.jacc.2010.03.083] [Cited by in Crossref: 156] [Cited by in F6Publishing: 109] [Article Influence: 14.2] [Reference Citation Analysis]
2 Alpendurada F, O’Hanlon R, Prasad SK. Cardiovascular magnetic resonance of cardiomyopathies. Curr Cardiol Rep. 2009;11:61-69. [PMID: 19091177 DOI: 10.1007/s11886-009-0010-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
3 Akcay A, Salcioglu Z, Oztarhan K, Tugcu D, Aydogan G, Ayaz NA, Bornaun H, Sen HS, Akici F, Akdana B. Cardiac T2* MRI assessment in patients with thalassaemia major and its effect on the preference of chelation therapy. Int J Hematol 2014;99:706-13. [PMID: 24719246 DOI: 10.1007/s12185-014-1575-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
4 Kirk P, Roughton M, Porter JB, Walker JM, Tanner MA, Patel J, Wu D, Taylor J, Westwood MA, Anderson LJ. Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation. 2009;120:1961-1968. [PMID: 19801505 DOI: 10.1161/circulationaha.109.874487] [Cited by in Crossref: 349] [Cited by in F6Publishing: 137] [Article Influence: 29.1] [Reference Citation Analysis]
5 Belhoul KM, Bakir ML, Kadhim AM, Dewedar HE, Eldin MS, Alkhaja FA. Prevalence of iron overload complications among patients with b-thalassemia major treated at Dubai Thalassemia Centre. Ann Saudi Med 2013;33:18-21. [PMID: 23458935 DOI: 10.5144/0256-4947.2013.18] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
6 Chalmers AW, Shammo JM. Evaluation of a new tablet formulation of deferasirox to reduce chronic iron overload after long-term blood transfusions. Ther Clin Risk Manag 2016;12:201-8. [PMID: 26929633 DOI: 10.2147/TCRM.S82449] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
7 Modell B, Harris R, Lane B, Khan M, Darlison M, Petrou M, Old J, Layton M, Varnavides L. Informed choice in genetic screening for thalassaemia during pregnancy: audit from a national confidential inquiry. BMJ 2000;320:337-41. [PMID: 10657326 DOI: 10.1136/bmj.320.7231.337] [Cited by in Crossref: 62] [Cited by in F6Publishing: 52] [Article Influence: 3.0] [Reference Citation Analysis]
8 Modell B, Khan M, Darlison M, Westwood MA, Ingram D, Pennell DJ. Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2008;10:42. [PMID: 18817553 DOI: 10.1186/1532-429x-10-42] [Cited by in Crossref: 307] [Cited by in F6Publishing: 131] [Article Influence: 23.6] [Reference Citation Analysis]
9 Alpendurada F, Smith GC, Carpenter JP, Nair SV, Tanner MA, Banya W, Dessi C, Galanello R, Walker JM, Pennell DJ. Effects of combined deferiprone with deferoxamine on right ventricular function in thalassaemia major. J Cardiovasc Magn Reson 2012;14:8. [PMID: 22277065 DOI: 10.1186/1532-429X-14-8] [Cited by in Crossref: 24] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
10 Qari MH, Wali Y, Albagshi MH, Alshahrani M, Alzahrani A, Alhijji IA, Almomen A, Aljefri A, Al Saeed HH, Abdullah S, Al Rustumani A, Mahour K, Mousa SA. Regional consensus opinion for the management of Beta thalassemia major in the Arabian Gulf area. Orphanet J Rare Dis 2013;8:143. [PMID: 24044606 DOI: 10.1186/1750-1172-8-143] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
11 Arezes J, Costa M, Vieira I, Dias V, Kong XL, Fernandes R, Vos M, Carlsson A, Rikers Y, Porto G, Rangel M, Hider RC, Pinto JP. Non-transferrin-bound iron (NTBI) uptake by T lymphocytes: evidence for the selective acquisition of oligomeric ferric citrate species. PLoS One 2013;8:e79870. [PMID: 24278199 DOI: 10.1371/journal.pone.0079870] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
12 Barton JC. Optimal management strategies for chronic iron overload. Drugs 2007;67:685-700. [PMID: 17385941 DOI: 10.2165/00003495-200767050-00004] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
13 Kirk P, Sheppard M, Carpenter JP, Anderson L, He T, St Pierre T, Galanello R, Catani G, Wood J, Fucharoen S, Porter JB, Walker JM, Forni GL, Pennell DJ. Post-mortem study of the association between cardiac iron and fibrosis in transfusion dependent anaemia. J Cardiovasc Magn Reson 2017;19:36. [PMID: 28343449 DOI: 10.1186/s12968-017-0349-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
14 Andreani M, Testi M, Gaziev J, Condello R, Bontadini A, Tazzari PL, Ricci F, De Felice L, Agostini F, Fraboni D, Ferrari G, Battarra M, Troiano M, Sodani P, Lucarelli G. Quantitatively different red cell/nucleated cell chimerism in patients with long-term, persistent hematopoietic mixed chimerism after bone marrow transplantation for thalassemia major or sickle cell disease. Haematologica 2011;96:128-33. [PMID: 20935000 DOI: 10.3324/haematol.2010.031013] [Cited by in Crossref: 63] [Cited by in F6Publishing: 62] [Article Influence: 5.7] [Reference Citation Analysis]
15 Wood JC. History and current impact of cardiac magnetic resonance imaging on the management of iron overload. Circulation 2009;120:1937-9. [PMID: 19884464 DOI: 10.1161/CIRCULATIONAHA.109.907196] [Cited by in Crossref: 52] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
16 Silvilairat S, Charoenkwan P, Saekho S, Tantiworawit A, Chattipakorn N. Carvedilol improves left ventricular diastolic dysfunction in patients with transfusion-dependent thalassemia. Ann Pediatr Cardiol 2021;14:152-8. [PMID: 34103853 DOI: 10.4103/apc.APC_63_20] [Reference Citation Analysis]
17 Ward A, Caro JJ, Green TC, Huybrechts K, Arana A, Wait S, Eleftheriou A. An international survey of patients with thalassemia major and their views about sustaining life-long desferrioxamine use. BMC Clin Pharmacol 2002;2:3. [PMID: 12015817 DOI: 10.1186/1472-6904-2-3] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 1.1] [Reference Citation Analysis]
18 Kontoghiorghes GJ, Kleanthous M, Kontoghiorghe CN. The History of Deferiprone (L1) and the Paradigm of the Complete Treatment of Iron Overload in Thalassaemia. Mediterr J Hematol Infect Dis 2020;12:e2020011. [PMID: 31934321 DOI: 10.4084/MJHID.2020.011] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
19 Otto-Duessel M, Brewer C, Gonzalez I, Nick H, Wood JC. Safety and efficacy of combined chelation therapy with deferasirox and deferoxamine in a gerbil model of iron overload. Acta Haematol 2008;120:123-8. [PMID: 19018129 DOI: 10.1159/000174757] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
20 Kayrak M, Acar K, Gul EE, Ozbek O, Abdulhalikov T, Sonmez O, Alibaşiç H. The Association between Myocardial Iron Load and Ventricular Repolarization Parameters in Asymptomatic Beta-Thalassemia Patients. Adv Hematol 2012;2012:170510. [PMID: 22666259 DOI: 10.1155/2012/170510] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
21 Carpenter JP, He T, Kirk P, Roughton M, Anderson LJ, de Noronha SV, Baksi AJ, Sheppard MN, Porter JB, Walker JM, Wood JC, Forni G, Catani G, Matta G, Fucharoen S, Fleming A, House M, Black G, Firmin DN, St Pierre TG, Pennell DJ. Calibration of myocardial T2 and T1 against iron concentration. J Cardiovasc Magn Reson 2014;16:62. [PMID: 25158620 DOI: 10.1186/s12968-014-0062-4] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
22 Yang G, Shi W, Hu X, Zhang J, Gong Z, Guo X, Ren Z, Zeng F. Therapeutic effects of induced pluripotent stem cells in chimeric mice with β-thalassemia. Haematologica 2014;99:1304-11. [PMID: 24816238 DOI: 10.3324/haematol.2013.087916] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
23 Crichton RR, Ward RJ, Hider RC. The Efficacy of Iron Chelators for Removing Iron from Specific Brain Regions and the Pituitary-Ironing out the Brain. Pharmaceuticals (Basel) 2019;12:E138. [PMID: 31533229 DOI: 10.3390/ph12030138] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
24 Bentley A, Gillard S, Spino M, Connelly J, Tricta F. Cost-utility analysis of deferiprone for the treatment of β-thalassaemia patients with chronic iron overload: a UK perspective. Pharmacoeconomics. 2013;31:807-822. [PMID: 23868464 DOI: 10.1007/s40273-013-0076-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
25 Motta I, Bou-Fakhredin R, Taher AT, Cappellini MD. Beta Thalassemia: New Therapeutic Options Beyond Transfusion and Iron Chelation. Drugs 2020;80:1053-63. [PMID: 32557398 DOI: 10.1007/s40265-020-01341-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 12.0] [Reference Citation Analysis]
26 Carpenter JP, He T, Kirk P, Roughton M, Anderson LJ, de Noronha SV, Sheppard MN, Porter JB, Walker JM, Wood JC, Galanello R, Forni G, Catani G, Matta G, Fucharoen S, Fleming A, House MJ, Black G, Firmin DN, St Pierre TG, Pennell DJ. On T2* magnetic resonance and cardiac iron. Circulation 2011;123:1519-28. [PMID: 21444881 DOI: 10.1161/CIRCULATIONAHA.110.007641] [Cited by in Crossref: 289] [Cited by in F6Publishing: 119] [Article Influence: 28.9] [Reference Citation Analysis]
27 Aessopos A, Berdoukas V, Tsironi M. The heart in transfusion dependent homozygous thalassaemia today--prediction, prevention and management. Eur J Haematol 2008;80:93-106. [PMID: 18081719 DOI: 10.1111/j.1600-0609.2007.01018.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 2.2] [Reference Citation Analysis]
28 Koren A, Profeta L, Zalman L, Palmor H, Levin C, Zamir RB, Shalev S, Blondheim O. Prevention of β Thalassemia in Northern Israel - a Cost-Benefit Analysis. Mediterr J Hematol Infect Dis 2014;6:e2014012. [PMID: 24678389 DOI: 10.4084/MJHID.2014.012] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 3.6] [Reference Citation Analysis]
29 Pepe A, Rossi G, Bentley A, Putti MC, Frizziero L, D'Ascola DG, Cuccia L, Spasiano A, Filosa A, Caruso V, Hanif A, Meloni A. Cost-Utility Analysis of Three Iron Chelators Used in Monotherapy for the Treatment of Chronic Iron Overload in β-Thalassaemia Major Patients: An Italian Perspective. Clin Drug Investig 2017;37:453-64. [PMID: 28185140 DOI: 10.1007/s40261-017-0496-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
30 Hussein AA, Hamidieh AA, Elhaddad A, Ramzi M, Othman TB, Hussain F, Dennison D, Ahmed P, Abboud M, Al-Ahmari A, Wahadneh A, Fathy J, Bekadja MA, Al-Kindi S, Benchekroun S, Ibrahim A, Behfar M, Samra M, Ladeb S, Adil S, El-Solh H, Ayas M, Aljurf M, Ghavamzadeh A, Al-Seraihy A; Pediatric Cancer Working Committee of the Eastern Mediterranean Blood and Marrow Transplantation (EMBMT) Group. First report of pediatric hematopoietic stem cell transplantation activities in the eastern mediterranean region from 1984 to 2011: on behalf of the pediatric cancer working committee of the eastern mediterranean blood and marrow transplantation group. Bone Marrow Transplant 2017;52:120-5. [PMID: 27618684 DOI: 10.1038/bmt.2016.209] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.4] [Reference Citation Analysis]
31 Lidén M, Adrian D, Widell J, Uggla B, Thunberg P. Quantitative T2* imaging of iron overload in a non-dedicated center - Normal variation, repeatability and reader variation. Eur J Radiol Open 2021;8:100357. [PMID: 34095355 DOI: 10.1016/j.ejro.2021.100357] [Reference Citation Analysis]
32 Alam MH, Auger D, McGill LA, Smith GC, He T, Izgi C, Baksi AJ, Wage R, Drivas P, Firmin DN, Pennell DJ. Comparison of 3 T and 1.5 T for T2* magnetic resonance of tissue iron. J Cardiovasc Magn Reson 2016;18:40. [PMID: 27391316 DOI: 10.1186/s12968-016-0259-9] [Cited by in Crossref: 26] [Cited by in F6Publishing: 17] [Article Influence: 5.2] [Reference Citation Analysis]
33 Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, Pibiri M, Nair SV, Walker JM, Pennell DJ. Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction. J Cardiovasc Magn Reson. 2008;10:12. [PMID: 18298856 DOI: 10.1186/1532429x1012] [Reference Citation Analysis]
34 Goulas V, Kourakli-Symeonidis A, Camoutsis C. Comparative effects of three iron chelation therapies on the quality of life of greek patients with homozygous transfusion-dependent Beta-thalassemia. ISRN Hematol 2012;2012:139862. [PMID: 23316378 DOI: 10.5402/2012/139862] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
35 Jamuar SS, Lai AH. Safety and efficacy of iron chelation therapy with deferiprone in patients with transfusion-dependent thalassemia. Ther Adv Hematol 2012;3:299-307. [PMID: 23616917 DOI: 10.1177/2040620712450252] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
36 Yu B, Yang Y, Liu Q, Zhan A, Yang Y, Liu H. A Novel Star Like Eight-Arm Polyethylene Glycol-Deferoxamine Conjugate for Iron Overload Therapy. Pharmaceutics 2020;12:E329. [PMID: 32272723 DOI: 10.3390/pharmaceutics12040329] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
37 Hamed EA, ElMelegy NT. Renal functions in pediatric patients with beta-thalassemia major: relation to chelation therapy: original prospective study. Ital J Pediatr 2010;36:39. [PMID: 20500848 DOI: 10.1186/1824-7288-36-39] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
38 Kontoghiorghe CN, Andreou N, Constantinou K, Kontoghiorghes GJ. World health dilemmas: Orphan and rare diseases, orphan drugs and orphan patients. World J Methodol 2014;4:163-88. [PMID: 25332915 DOI: 10.5662/wjm.v4.i3.163] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
39 Olivieri NF, Brittenham GM. Management of the thalassemias. Cold Spring Harb Perspect Med 2013;3:a011767. [PMID: 23732853 DOI: 10.1101/cshperspect.a011767] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
40 Shenoy N, Vallumsetla N, Rachmilewitz E, Verma A, Ginzburg Y. Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome. Blood 2014;124:873-81. [PMID: 24923296 DOI: 10.1182/blood-2014-03-563221] [Cited by in Crossref: 64] [Cited by in F6Publishing: 53] [Article Influence: 9.1] [Reference Citation Analysis]
41 Chonat S, Quinn CT. Current Standards of Care and Long Term Outcomes for Thalassemia and Sickle Cell Disease. Adv Exp Med Biol 2017;1013:59-87. [PMID: 29127677 DOI: 10.1007/978-1-4939-7299-9_3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
42 Sadaf A, Hasan B, Das JK, Colan S, Alvi N. Calcium channel blockers for preventing cardiomyopathy due to iron overload in people with transfusion-dependent beta thalassaemia. Cochrane Database Syst Rev 2018;7:CD011626. [PMID: 29998494 DOI: 10.1002/14651858.CD011626.pub2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
43 Wood JC. Estimating tissue iron burden: current status and future prospects. Br J Haematol 2015;170:15-28. [PMID: 25765344 DOI: 10.1111/bjh.13374] [Cited by in Crossref: 71] [Cited by in F6Publishing: 60] [Article Influence: 11.8] [Reference Citation Analysis]
44 Westwood MA, Firmin DN, Gildo M, Renzo G, Stathis G, Markissia K, Vasili B, Pennell DJ. Intercentre reproducibility of magnetic resonance T2* measurements of myocardial iron in thalassaemia. Int J Cardiovasc Imaging 2005;21:531-8. [PMID: 16175443 DOI: 10.1007/s10554-005-0651-2] [Cited by in Crossref: 77] [Cited by in F6Publishing: 70] [Article Influence: 5.1] [Reference Citation Analysis]
45 Moorthie S, Blencowe H, W Darlison M, Lawn JE, Mastroiacovo P, Morris JK, Modell B; Congenital Disorders Expert Group. An overview of concepts and approaches used in estimating the burden of congenital disorders globally. J Community Genet 2018;9:347-62. [PMID: 29022220 DOI: 10.1007/s12687-017-0335-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
46 Taher A, El-Beshlawy A, Elalfy MS, Al Zir K, Daar S, Habr D, Kriemler-Krahn U, Hmissi A, Al Jefri A. Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study. Eur J Haematol 2009;82:458-65. [PMID: 19187278 DOI: 10.1111/j.1600-0609.2009.01228.x] [Cited by in Crossref: 91] [Cited by in F6Publishing: 87] [Article Influence: 7.6] [Reference Citation Analysis]
47 Carpenter JP, Roughton M, Pennell DJ; Myocardial Iron in Thalassemia (MINT) Investigators. International survey of T2* cardiovascular magnetic resonance in β-thalassemia major. Haematologica 2013;98:1368-74. [PMID: 23812939 DOI: 10.3324/haematol.2013.083634] [Cited by in Crossref: 49] [Cited by in F6Publishing: 37] [Article Influence: 6.1] [Reference Citation Analysis]
48 Tyan PI, Radwan AH, Eid A, Haddad AG, Wehbe D, Taher AT. Novel approach to reactive oxygen species in nontransfusion-dependent thalassemia. Biomed Res Int 2014;2014:350432. [PMID: 25121095 DOI: 10.1155/2014/350432] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
49 Porter JB, Evangeli M, El-Beshlawy A. Challenges of adherence and persistence with iron chelation therapy. Int J Hematol 2011;94:453-60. [PMID: 21993873 DOI: 10.1007/s12185-011-0927-3] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.6] [Reference Citation Analysis]
50 Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, Pibiri M, Nair SV, Walker JM, Pennell DJ. Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction. J Cardiovasc Magn Reson 2008;10:12. [PMID: 18298856 DOI: 10.1186/1532-429X-10-12] [Cited by in Crossref: 136] [Cited by in F6Publishing: 57] [Article Influence: 10.5] [Reference Citation Analysis]
51 Bollig C, Schell LK, Rücker G, Allert R, Motschall E, Niemeyer CM, Bassler D, Meerpohl JJ. Deferasirox for managing iron overload in people with thalassaemia. Cochrane Database Syst Rev 2017;8:CD007476. [PMID: 28809446 DOI: 10.1002/14651858.CD007476.pub3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
52 Andreani M, Testi M, Battarra M, Lucarelli G. Split chimerism between nucleated and red blood cells after bone marrow transplantation for haemoglobinopathies. Chimerism 2011;2:21-2. [PMID: 21547033 DOI: 10.4161/chim.2.1.15057] [Cited by in F6Publishing: 11] [Reference Citation Analysis]
53 Ward RJ, Dexter DT, Martin-Bastida A, Crichton RR. Is Chelation Therapy a Potential Treatment for Parkinson's Disease? Int J Mol Sci 2021;22:3338. [PMID: 33805195 DOI: 10.3390/ijms22073338] [Reference Citation Analysis]
54 Coifman KG, Ross GS, Kleinert D, Giardina P. Negative affect differentiation and adherence during treatment for thalassemia. Int J Behav Med 2014;21:160-8. [PMID: 23086716 DOI: 10.1007/s12529-012-9277-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
55 Bellanti F, Del Vecchio GC, Putti MC, Cosmi C, Fotzi I, Bakshi SD, Danhof M, Della Pasqua O. Model-Based Optimisation of Deferoxamine Chelation Therapy. Pharm Res 2016;33:498-509. [PMID: 26555666 DOI: 10.1007/s11095-015-1805-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
56 Fujikura K, Golive AD, Ando T, Corado FM, Shitole SG, Kizer JR, Shah AM, Prince MR, Spevack DM, Garcia MJ. Increased Iron Deposition Is Directly Associated With Myocardial Dysfunction in Patients With Sickle Cell Disease. JACC Cardiovasc Imaging 2018;11:279-80. [PMID: 28412428 DOI: 10.1016/j.jcmg.2017.02.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
57 Kontoghiorghe CN, Kontoghiorghes GJ. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes. Drug Des Devel Ther 2016;10:465-81. [PMID: 26893541 DOI: 10.2147/DDDT.S79458] [Cited by in Crossref: 49] [Cited by in F6Publishing: 28] [Article Influence: 9.8] [Reference Citation Analysis]
58 Aronow WS. Management of cardiac hemochromatosis. Arch Med Sci 2018;14:560-8. [PMID: 29765443 DOI: 10.5114/aoms.2017.68729] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
59 Vassiliadis T, Garipidou V, Perifanis V, Tziomalos K, Giouleme O, Patsiaoura K, Avramidis M, Nikolaidis N, Vakalopoulou S, Tsitouridis I, Antoniadis A, Semertzidis P, Kioumi A, Premetis E, Eugenidis N. A case of successful management with splenectomy of intractable ascites due to congenital dyserythropoietic anemia type II-induced cirrhosis. World J Gastroenterol 2006;12:818-21. [PMID: 16521204 DOI: 10.3748/wjg.v12.i5.818] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
60 Kleinman S, Stassinopoulos A. Risks associated with red blood cell transfusions: potential benefits from application of pathogen inactivation. Transfusion 2015;55:2983-3000. [PMID: 26303806 DOI: 10.1111/trf.13259] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 4.7] [Reference Citation Analysis]
61 Radke T, Paulukonis S, Hulihan MM, Feuchtbaum L. Providers' Perspectives on Treating Patients With Thalassemia. J Pediatr Hematol Oncol 2019;41:e421-6. [PMID: 31368920 DOI: 10.1097/MPH.0000000000001573] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
62 Hamilton JL, Kizhakkedathu JN. Polymeric nanocarriers for the treatment of systemic iron overload. Mol Cell Ther 2015;3:3. [PMID: 26056604 DOI: 10.1186/s40591-015-0039-1] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 3.7] [Reference Citation Analysis]
63 Tanaka C. Clinical pharmacology of deferasirox. Clin Pharmacokinet 2014;53:679-94. [PMID: 24996374 DOI: 10.1007/s40262-014-0151-4] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
64 Nai A, Pagani A, Mandelli G, Lidonnici MR, Silvestri L, Ferrari G, Camaschella C. Deletion of TMPRSS6 attenuates the phenotype in a mouse model of β-thalassemia. Blood 2012;119:5021-9. [PMID: 22490684 DOI: 10.1182/blood-2012-01-401885] [Cited by in Crossref: 105] [Cited by in F6Publishing: 100] [Article Influence: 11.7] [Reference Citation Analysis]
65 Ladis V, Chouliaras G, Berdoukas V, Moraitis P, Zannikos K, Berdoussi E, Kattamis C. Relation of chelation regimes to cardiac mortality and morbidity in patients with thalassaemia major: an observational study from a large Greek Unit. Eur J Haematol 2010;85:335-44. [PMID: 20561034 DOI: 10.1111/j.1600-0609.2010.01491.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
66 Kim KH, Kim JW, Rhee JY, Kim MK, Kim BS, Kim I, Bang SM, Yoon SS, Lee JS, Han KS, Park S, Kim BK. Cost analysis of iron-related complications in a single institute. Korean J Intern Med 2009;24:33-6. [PMID: 19270479 DOI: 10.3904/kjim.2009.24.1.33] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
67 Noori T, Ghazisaeedi M, Aliabad GM, Mehdipour Y, Mehraeen E, Conte R, Safdari R. International Comparison of Thalassemia Registries: Challenges and Opportunities. Acta Inform Med 2019;27:58-63. [PMID: 31213746 DOI: 10.5455/aim.2019.27.58-63] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
68 Smith GC, Alpendurada F, Carpenter JP, Alam MH, Berdoukas V, Karagiorga M, Ladis V, Piga A, Aessopos A, Gotsis ED, Tanner MA, Westwood MA, Galanello R, Roughton M, Pennell DJ. Effect of deferiprone or deferoxamine on right ventricular function in thalassemia major patients with myocardial iron overload. J Cardiovasc Magn Reson 2011;13:34. [PMID: 21733147 DOI: 10.1186/1532-429X-13-34] [Cited by in Crossref: 23] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
69 de Montalembert M, Ribeil JA, Brousse V, Guerci-Bresler A, Stamatoullas A, Vannier JP, Dumesnil C, Lahary A, Touati M, Bouabdallah K, Cavazzana M, Chauzit E, Baptiste A, Lefebvre T, Puy H, Elie C, Karim Z, Ernst O, Rose C. Cardiac iron overload in chronically transfused patients with thalassemia, sickle cell anemia, or myelodysplastic syndrome. PLoS One 2017;12:e0172147. [PMID: 28257476 DOI: 10.1371/journal.pone.0172147] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 7.8] [Reference Citation Analysis]
70 Lesic B, Foulon J, Carniel E. Comparison of the effects of deferiprone versus deferoxamine on growth and virulence of Yersinia enterocolitica. Antimicrob Agents Chemother 2002;46:1741-5. [PMID: 12019084 DOI: 10.1128/AAC.46.6.1741-1745.2002] [Cited by in Crossref: 40] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
71 Kwiatkowski JL, Kim HY, Thompson AA, Quinn CT, Mueller BU, Odame I, Giardina PJ, Vichinsky EP, Boudreaux JM, Cohen AR, Porter JB, Coates T, Olivieri NF, Neufeld EJ; Thalassemia Clinical Research Network. Chelation use and iron burden in North American and British thalassemia patients: a report from the Thalassemia Longitudinal Cohort. Blood 2012;119:2746-53. [PMID: 22279056 DOI: 10.1182/blood-2011-04-344507] [Cited by in Crossref: 59] [Cited by in F6Publishing: 46] [Article Influence: 6.6] [Reference Citation Analysis]
72 Grady RW, Galanello R, Randolph RE, Kleinert DA, Dessi C, Giardina PJ. Toward optimizing the use of deferasirox: potential benefits of combined use with deferoxamine. Haematologica 2013;98:129-35. [PMID: 22875626 DOI: 10.3324/haematol.2012.070607] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 2.6] [Reference Citation Analysis]
73 Chattipakorn N, Kumfu S, Fucharoen S, Chattipakorn S. Calcium channels and iron uptake into the heart. World J Cardiol 2011;3:215-8. [PMID: 21860702 DOI: 10.4330/wjc.v3.i7.215] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
74 Taher AT, Origa R, Perrotta S, Kourakli A, Ruffo GB, Kattamis A, Goh AS, Cortoos A, Huang V, Weill M, Merino Herranz R, Porter JB. New film-coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or lower-risk MDS: Results of the randomized, phase II ECLIPSE study. Am J Hematol 2017;92:420-8. [PMID: 28142202 DOI: 10.1002/ajh.24668] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 9.3] [Reference Citation Analysis]
75 Telfer PT, Warburton F, Christou S, Hadjigavriel M, Sitarou M, Kolnagou A, Angastiniotis M. Improved survival in thalassemia major patients on switching from desferrioxamine to combined chelation therapy with desferrioxamine and deferiprone. Haematologica 2009;94:1777-8. [PMID: 19815834 DOI: 10.3324/haematol.2009.009118] [Cited by in Crossref: 52] [Cited by in F6Publishing: 55] [Article Influence: 4.3] [Reference Citation Analysis]
76 Luangasanatip N, Chaiyakunapruk N, Upakdee N, Wong P. Iron-chelating therapies in a transfusion-dependent thalassaemia population in Thailand: a cost-effectiveness study. Clin Drug Investig. 2011;31:493-505. [PMID: 21627338 DOI: 10.2165/11587120-000000000-00000] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
77 Carpenter JP, Alpendurada F, Deac M, Maceira A, Garbowski M, Kirk P, Walker JM, Porter JB, Shah F, Banya W, He T, Smith GC, Pennell DJ. Right ventricular volumes and function in thalassemia major patients in the absence of myocardial iron overload. J Cardiovasc Magn Reson 2010;12:24. [PMID: 20416084 DOI: 10.1186/1532-429X-12-24] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
78 Thuret I, Pondarré C, Loundou A, Steschenko D, Girot R, Bachir D, Rose C, Barlogis V, Donadieu J, de Montalembert M, Hagege I, Pegourie B, Berger C, Micheau M, Bernaudin F, Leblanc T, Lutz L, Galactéros F, Siméoni MC, Badens C. Complications and treatment of patients with β-thalassemia in France: results of the National Registry. Haematologica 2010;95:724-9. [PMID: 20007138 DOI: 10.3324/haematol.2009.018051] [Cited by in Crossref: 49] [Cited by in F6Publishing: 40] [Article Influence: 4.1] [Reference Citation Analysis]
79 Cappellini MD. Exjade(R) (deferasirox, ICL670) in the treatment of chronic iron overload associated with blood transfusion. Ther Clin Risk Manag 2007;3:291-9. [PMID: 18360637 DOI: 10.2147/tcrm.2007.3.2.291] [Cited by in Crossref: 46] [Cited by in F6Publishing: 38] [Article Influence: 4.6] [Reference Citation Analysis]
80 Yang G, Liu R, Peng P, Long L, Zhang X, Yang W, Tan S, Pan H, Long X, He T, Anderson L, Lai Y. How early can myocardial iron overload occur in beta thalassemia major? PLoS One 2014;9:e85379. [PMID: 24465548 DOI: 10.1371/journal.pone.0085379] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
81 Petrou M. Screening for beta thalassaemia. Indian J Hum Genet 2010;16:1-5. [PMID: 20838484 DOI: 10.4103/0971-6866.64934] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
82 Kontoghiorghes GJ, Neocleous K, Kolnagou A. Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine. Drug Saf 2003;26:553-84. [PMID: 12825969 DOI: 10.2165/00002018-200326080-00003] [Cited by in Crossref: 74] [Cited by in F6Publishing: 75] [Article Influence: 4.1] [Reference Citation Analysis]
83 Saliba AN, Harb AR, Taher AT. Iron chelation therapy in transfusion-dependent thalassemia patients: current strategies and future directions. J Blood Med 2015;6:197-209. [PMID: 26124688 DOI: 10.2147/JBM.S72463] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
84 Chaosuwannakit N, Makarawate P, Wanitpongpun C. The Importance of Cardiac T2* Magnetic Resonance Imaging for Monitoring Cardiac Siderosis in Thalassemia Major Patients. Tomography 2021;7:130-8. [PMID: 33919601 DOI: 10.3390/tomography7020012] [Reference Citation Analysis]
85 Veríssimo MP, Loggetto SR, Fabron Junior A, Baldanzi GR, Hamerschlak N, Fernandes JL, Araujo Ada S, Lobo CL, Fertrin KY, Berdoukas VA, Galanello R. Brazilian Thalassemia Association protocol for iron chelation therapy in patients under regular transfusion. Rev Bras Hematol Hemoter 2013;35:428-34. [PMID: 24478610 DOI: 10.5581/1516-8484.20130106] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
86 Liaska A, Petrou P, Georgakopoulos CD, Diamanti R, Papaconstantinou D, Kanakis MG, Georgalas I. β-Thalassemia and ocular implications: a systematic review. BMC Ophthalmol 2016;16:102. [PMID: 27390837 DOI: 10.1186/s12886-016-0285-2] [Cited by in Crossref: 29] [Cited by in F6Publishing: 16] [Article Influence: 5.8] [Reference Citation Analysis]
87 Oudit GY, Trivieri MG, Khaper N, Liu PP, Backx PH. Role of L-type Ca2+ channels in iron transport and iron-overload cardiomyopathy. J Mol Med (Berl). 2006;84:349-364. [PMID: 16604332 DOI: 10.1007/s00109-005-0029-x] [Cited by in Crossref: 127] [Cited by in F6Publishing: 120] [Article Influence: 8.5] [Reference Citation Analysis]
88 Aessopos A, Berdoukas V, Tsironi M. Prevention of cardiomyopathy in transfusion-dependent homozygous thalassaemia today and the role of cardiac magnetic resonance imaging. Adv Hematol 2009;2009:964897. [PMID: 19960043 DOI: 10.1155/2009/964897] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
89 Wood JC. Diagnosis and management of transfusion iron overload: the role of imaging. Am J Hematol 2007;82:1132-5. [PMID: 17963249 DOI: 10.1002/ajh.21099] [Cited by in Crossref: 55] [Cited by in F6Publishing: 41] [Article Influence: 4.2] [Reference Citation Analysis]
90 Kolnagou A, Kontoghiorghe CN, Kontoghiorghes GJ. Transition of Thalassaemia and Friedreich ataxia from fatal to chronic diseases. World J Methodol 2014;4:197-218. [PMID: 25541601 DOI: 10.5662/wjm.v4.i4.197] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
91 Marengo-Rowe AJ. The thalassemias and related disorders. Proc (Bayl Univ Med Cent) 2007;20:27-31. [PMID: 17256039 DOI: 10.1080/08998280.2007.11928230] [Cited by in Crossref: 35] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
92 Berdoukas V, Chouliaras G, Moraitis P, Zannikos K, Berdoussi E, Ladis V. The efficacy of iron chelator regimes in reducing cardiac and hepatic iron in patients with thalassaemia major: a clinical observational study. J Cardiovasc Magn Reson 2009;11:20. [PMID: 19558722 DOI: 10.1186/1532-429X-11-20] [Cited by in Crossref: 47] [Cited by in F6Publishing: 21] [Article Influence: 3.9] [Reference Citation Analysis]
93 Wonke B, De Sanctis V. Clinical aspects of transfusional iron overload. Reviews in Clinical and Experimental Hematology 2001;4:322-36. [DOI: 10.1046/j.1468-0734.2000.00023.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
94 Modell B, Khan M, Darlison M, Westwood MA, Ingram D, Pennell DJ. Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2008;10:42. [PMID: 18817553 DOI: 10.1186/1532429x1042] [Reference Citation Analysis]
95 Stoyanova E, Trudel M, Felfly H, Lemsaddek W, Garcia D, Cloutier G. Vascular endothelial dysfunction in β-thalassemia occurs despite increased eNOS expression and preserved vascular smooth muscle cell reactivity to NO. PLoS One 2012;7:e38089. [PMID: 22723848 DOI: 10.1371/journal.pone.0038089] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
96 Sidhu S, Kakkar S, Dewan P, Bansal N, Sobti PC. Adherence to Iron Chelation Therapy and Its Determinants. Int J Hematol Oncol Stem Cell Res 2021;15:27-34. [PMID: 33613898 DOI: 10.18502/ijhoscr.v15i1.5247] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
97 Meerpohl JJ, Schell LK, Rücker G, Motschall E, Fleeman N, Niemeyer CM, Bassler D. Deferasirox for managing transfusional iron overload in people with sickle cell disease. Cochrane Database Syst Rev 2014;5:CD007477. [PMID: 24893174 DOI: 10.1002/14651858.CD007477.pub3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]